Reduced Bone Tissue Heterogeneity with Bisphosphonate Treatment in Postmenopausal Women with Fractures
ثبت نشده
چکیده
+Donnelly, E; Meredith, DS; Gladnick, BP; Rebolledo BJ; Lane JM; Boskey, AL +Hospital for Special Surgery, New York, NY [email protected] INTRODUCTION Bisphosphonate therapy reduces fracture incidence in osteoporotic patients, and the safety and efficacy of alendronate is generally preserved with treatment durations as long as 10 years [1]. Although no significant association between bisphosphonate use and subtrochanteric (ST) fracture risk was detected in recent analyses of datasets from large trials [2], identification of a rare atypical ST fracture pattern specifically associated with long-term bisphosphonate treatment [3] suggests that bisphosphonate use may alter bone quality and fracture resistance in a subset of patients. Therefore, our objective was to investigate the effect of bisphosphonate treatment on bone tissue composition near femoral fracture sites.
منابع مشابه
Economic Analysis of Bisphosphonate Use after Distal Radius Fracture for Prevention of Hip Fracture
Background: Osteoporosis is a common condition among the elderly population, and is associated with an increased risk of fracture. One of the most common fragility fractures involve the distal radius, and are associated with risk of subsequent fragility fracture. Early treatment with bisphosphonates has been suggested to decrease the population hip fracture burden. However, there have been no p...
متن کاملAtypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance.
Bisphosphonates are the most widely prescribed pharmacologic treatment for osteoporosis and reduce fracture risk in postmenopausal women by up to 50%. However, in the past decade these drugs have been associated with atypical femoral fractures (AFFs), rare fractures with a transverse, brittle morphology. The unusual fracture morphology suggests that bisphosphonate treatment may impair toughenin...
متن کاملZoledronic acid infusion for prevention and treatment of osteoporosis
Osteoporotic fractures are associated with significant morbidity, reduced quality of life, increased mortality, and high health care costs. Bisphosphonates are standard therapy for treatment of osteoporosis. However, patient compliance and persistence with oral weekly or monthly bisphosphonate therapy are suboptimal and may lead to reduced effectiveness. Zoledronic acid (ZOL) is an intravenous ...
متن کاملIntravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect
INTRODUCTION Osteoporosis is a disease characterized by low bone mineral density and poor bone quality resulting in reduced bone strength and increased risk of fracture. Oral bisphosphonates, first-line therapy for most patients with osteoporosis, are associated with suboptimal adherence to therapy due to factors that include a complex dosing regimen and gastrointestinal intolerance in some pat...
متن کاملEffects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis A Randomized Controlled Trial
DECLINING ESTROGEN LEVELS at menopause result in increased bone turnover and a loss of bone mass, with subsequent increases in bone fragility and the risk of bone fracture. Vertebral fracture, in particular, is a common consequence of osteoporosis and may be considered the hallmark fracture for osteoporosis in postmenopausal women. Because of the high frequency of vertebral fractures in patient...
متن کامل